Spots Global Cancer Trial Database for Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
Official Title: A Phase I, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor.
Study ID: NCT04689100
Conditions
Study Description
Brief Summary: This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.
Detailed Description: The objective of the trial is to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor. This study consists of two parts (Stage I and Stage II). Stage I was a dose escalation study, and Stage II was a dose expansion study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Luhe Hospital. Capital Medical University, Beijing, , China
Peking University Cancer Hospital, Beijing, , China
The first affiliated hospital of bengbu medical college, Bengbu, , China
The First People's Hospital of Changzhou, Changzhou, , China
Chongqing University Cancer Hospital, Chongqing, , China
The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, , China
Zhongshan Hospital, Shanghai, , China
The First Affiliated Hospital of Soochow University, Suzhou, , China
Henan Cancer Hospital, Zhengzhou, , China
Contact Details
Name: Xiugao Yang
Affiliation: Department of Medicine, CSPC Clinical Development Division
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
